CoChat
Sign Up
Cited by 201Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersCell death mechanisms and regulation

The DOI matches its Crossref record; 126 of the 127 references it cites were found in a registry or an index.

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy

Open access
Adkins, Irena, Fucikova, Jitka, Garg, Abhishek D, Agostinis, Patrizia, Špíšek, Radek·2014·OncoImmunology
DOI 10.4161/21624011.2014.968434PMC PMC4352954
Open this paper in CoChat — free accountOpen PDF

Abstract

The concept of immunogenic cancer cell death (ICD), as originally observed during the treatment with several chemotherapeutics or ionizing irradiation, has revolutionized the view on the development of new anticancer therapies. ICD is defined by endoplasmic reticulum (ER) stress response, reactive oxygen species (ROS) generation, emission of danger-associated molecular patterns and induction of antitumor immunity. Here we describe known and emerging cancer cell death-inducing physical modalities, such as ionizing irradiation, ultraviolet C light, Photodynamic Therapy (PDT) with Hypericin, high hydrostatic pressure (HHP) and hyperthermia (HT), which have been shown to elicit effective antitumor immunity. We discuss the evidence of ICD induced by these modalities in cancer patients together with their applicability in immunotherapeutic protocols and anticancer vaccine development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/21624011.2014.968434

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Timeline of the most important discoveries in the field of immunogenic cell death. Abbreviations: ATP, Adenosine triphosphate; CRT, calreticulin; DC, dendritic cell; HMGB1, high mobility group box 1; HSP90, heat shock protein 90; Hyp-PDT, photodynamic therapy with hypericin; ICD, immunogenic cell death; LRP, lipoprotein receptor-related proteins; MyD88, myeloid differentiation primary response gene 88; TLR, toll like receptor; UVC, ultraviolet light C.
Figure 1. Timeline of the most important discoveries in the field of immunogenic cell death. Abbreviations: ATP, Adenosine triphosphate; CRT, calreticulin; DC, dendritic cell; HMGB1, high mobility group box 1; HSP90, heat shock protein 90; Hyp-PDT, photodynamic therapy with hypericin; ICD, immunogenic cell death; LRP, lipoprotein receptor-related proteins; MyD88, myeloid differentiation primary response gene 88; TLR, toll like receptor; UVC, ultraviolet light C.CC BY · PubMed Central
Figure 2. A schematic representation of DC-based vaccine preparation using immunogenic HHP-killed tumor cells. Tumor cells treated with HHP (or other physical ICD-inducing modalities) expose various danger signals, so called DAMPs, in different stages of apoptosis. These DAMPs include calreticulin (CRT), heat shock proteins 70/90 (HSP70/90), HMGB1 and ATP. These molecules bind to respective cognate receptors like CD91 (for CRT/HSPs), TLR2/TLR4 (for HMGB1 or HSP70), P2RX7/P2RY2 (for ATP), respectively, on the cell surface of DCs. This leads to an enhanced engulfment of tumor cells and DC maturation characterized by upregulation of costimulatory molecules such as CD80, CD83, CD86 and HLA-DR, and by a distinct pro-inflammatory cytokine pattern. Activated DCs efficiently present tumor-specific antigens in the context of MHC class I and II molecules to T cells, inducing antitumor CD4+ and CD8+ T cell responses. Abbreviations: ATP, Adenosine triphosphate; CRT, calreticulin; CTL, cytotoxic T lymphocytes; DAMPs, danger-associated molecular patterns; DC, dendritic cell; HHP, high hydrostatic pressure; HMGB1, high mobility group box 1 HSP70, heat shock protein 70; HSP90, heat shock protein 90; ICD, immunogenic cell death; P2RX7, P2X purinoceptor 7; P2RY2, P2Y purinoceptor 2; RAGE, receptor for advanced glycation endproducts; TLR, toll like receptor.
Figure 2. A schematic representation of DC-based vaccine preparation using immunogenic HHP-killed tumor cells. Tumor cells treated with HHP (or other physical ICD-inducing modalities) expose various danger signals, so called DAMPs, in different stages of apoptosis. These DAMPs include calreticulin (CRT), heat shock proteins 70/90 (HSP70/90), HMGB1 and ATP. These molecules bind to respective cognate receptors like CD91 (for CRT/HSPs), TLR2/TLR4 (for HMGB1 or HSP70), P2RX7/P2RY2 (for ATP), respectively, on the cell surface of DCs. This leads to an enhanced engulfment of tumor cells and DC maturation characterized by upregulation of costimulatory molecules such as CD80, CD83, CD86 and HLA-DR, and by a distinct pro-inflammatory cytokine pattern. Activated DCs efficiently present tumor-specific antigens in the context of MHC class I and II molecules to T cells, inducing antitumor CD4+ and CD8+ T cell responses. Abbreviations: ATP, Adenosine triphosphate; CRT, calreticulin; CTL, cytotoxic T lymphocytes; DAMPs, danger-associated molecular patterns; DC, dendritic cell; HHP, high hydrostatic pressure; HMGB1, high mobility group box 1 HSP70, heat shock protein 70; HSP90, heat shock protein 90; ICD, immunogenic cell death; P2RX7, P2X purinoceptor 7; P2RY2, P2Y purinoceptor 2; RAGE, receptor for advanced glycation endproducts; TLR, toll like receptor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 10

  1. Korbelik M, 1996, Cancer Res, 56, 5647
  2. Strome SE, 2002, Cancer Res, 62, 1884
  3. Frey B, 2004, Cell Mol Biol (Noisy-Le-Grand), 50, 459
  4. Korn A, 2004, Cell Mol Biol (Noisy-Le-Grand), 50, 469
  5. Diehl P, 2008, Anticancer Res, 28, 3877
  6. Goldman Y, 2000, Cancer Res, 60, 350
  7. Shinitzky M, 2000, Isr Med Assoc J, 2, 615
  8. 10.1002/ijc.28766 · DOI
  9. Alecu M, 1998, Anticancer Res, 18, 4651
  10. Gollnick SO, 2002, Cancer Res, 62, 1604

Cited by

Sorted by citations

See all 201

Related

See all

Metadata

Authors
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P., & Špíšek, R.
Affiliations
  • Charles University (CZ)
  • KU Leuven (BE)
Corresponding author
  • Adkins, Irena
  • Špíšek, Radek
ORCID
Venue
OncoImmunology
Publisher
Informa UK Limited
Published
2014-11-03
Volume
3
Issue
12
Pages
e968434
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
DOI
10.4161/21624011.2014.968434
PMC
PMC4352954
OpenAlex
W2081035306
Cited by
200
References
127
Citations by year
2026: 8 · 2025: 16 · 2024: 12 · 2023: 20 · 2022: 17 · 2021: 19 · 2020: 24 · 2019: 17 · 2018: 15 · 2017: 18 · 2016: 22 · 2015: 11
FWCI
1.66
Type
journal article
Language
en
Open access
Licence
Locations
  • OncoImmunology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
immunogenic cancer cell death, physical agents, ionizing irradiation, ultraviolet C light, photodynamic therapy, hypericin, high hydrostatic pressure, hyperthermia, endoplasmic reticulum stress, reactive oxygen species, damage-associated molecular patterns, antitumor immunity, cancer immunotherapy, cancer vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review